title: Evidence for an interaction of halothane with the L-type Ca2+ channel in human myocardium.
abstract: BACKGROUND
  The present study was aimed at investigating the underlying mechanisms for the cardiac depressant effect of halothane. To test the hypothesis, whether there is an interaction of halothane with the L-type Ca2+ channels in human myocardium and whether this interaction has functional consequences for force generation in the human myocardium, effects of halothane were studied in human myocardial membranes and isolated cardiac preparations.
  
  
  METHODS
  The experiments were performed on isolated, electrically driven ventricular preparations (1 Hz, 37 degrees C) and cardiac membranes with radioligand binding experiments using 3H-PN 200-110. Myocardium from human failing and non-failing hearts was obtained at cardiac surgery.
  
  
  RESULTS
  Halothane produced a negative inotropic effect, which was similar in nonfailing and failing myocardium. Halothane shifted the concentration-response curve for the positive inotropic effect of the L-type Ca2+ channel agonist BayK 8644 to the right. The density of dihydropyridine receptors as judged from 3H-PN 200-110 radioligand binding experiments was similar in nonfailing and failing myocardium, whereas the density of beta-adrenoceptors was reduced. Halothane concentration dependently reduced the binding of 3H-PN 200-110, an antagonist at the 1,4 dihydropyridine receptor site of the Ca2+ channel, to myocardial membranes. Furthermore, halothane produced a rightward shift of the competition curve of BayK 8644 for binding of 3H-PN 200-110 to cardiac membranes.
  
  
  CONCLUSIONS
  In human ventricular myocardium, halothane exhibits an interaction with the L-type Ca2+ channel by interfering with its dihydropyridine binding sites. This may explain, at least in part, the observed negative inotropic effect of this agent and could hypothetically play a general role in its anesthetic effects.
authors.affiliation: Medizinische Klinik I, Universität München, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Schmidt
authors.forename: R H
authors.initials: RH
authors.lastname: Schwinger
authors.forename: S
authors.initials: S
authors.lastname: Böhm
authors.forename: P
authors.initials: P
authors.lastname: Uberfuhr
authors.forename: E
authors.initials: E
authors.lastname: Kreuzer
authors.forename: B
authors.initials: B
authors.lastname: Reichart
authors.forename: L
authors.initials: L
authors.lastname: Meyer
authors.forename: E
authors.initials: E
authors.lastname: Erdmann
authors.forename: M
authors.initials: M
authors.lastname: Böhm
mesh_terms: D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D001665:Binding Sites; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D006221:Halothane / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D017275:Isradipine / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000378:metabolism*
chemical_list: D015220:Calcium Channels; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D006221:Halothane; D017275:Isradipine